These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 27913540)

  • 1. Sickle cell disease: an inherited thrombophilia.
    Wun T; Brunson A
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):640-647. PubMed ID: 27913540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venous thromboembolism: risk factors for recurrence.
    Zhu T; Martinez I; Emmerich J
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):298-310. PubMed ID: 19228602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal duration of anticoagulation. Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests.
    Prandoni P; Barbar S; Milan M; Campello E; Spiezia L; Piovella C; Pesavento R
    Thromb Haemost; 2015 Jun; 113(6):1210-5. PubMed ID: 25119194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 coagulopathy and thrombosis: Analysis of hospital protocols in response to the rapidly evolving pandemic.
    Parks AL; Auerbach AD; Schnipper JL; Anstey JE; Sterken DG; Hecht TEH; Fang MC;
    Thromb Res; 2020 Dec; 196():355-358. PubMed ID: 32977136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Recurrence risk in venous thromboembolic disease after anticoagulation discontinuation].
    Calvo Romero JM
    Med Clin (Barc); 2013 Apr; 140(7):310-3. PubMed ID: 22995846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined hormonal contraception and the risk of venous thromboembolism: a guideline.
    ;
    Fertil Steril; 2017 Jan; 107(1):43-51. PubMed ID: 27793376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer and thrombosis: new insights to an old problem.
    Leiva O; Newcomb R; Connors JM; Al-Samkari H
    J Med Vasc; 2020 Nov; 45(6S):6S8-6S16. PubMed ID: 33276943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment.
    Santamaria MG; Agnelli G; Taliani MR; Prandoni P; Moia M; Bazzan M; Guazzaloca G; Ageno W; Bertoldi A; Silingardi M; Tomasi C; Ambrosio GB;
    Thromb Res; 2005; 116(4):301-6. PubMed ID: 16038714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deep venous thrombosis and venous thromboembolism prophylaxis.
    Buesing KL; Mullapudi B; Flowers KA
    Surg Clin North Am; 2015 Apr; 95(2):285-300. PubMed ID: 25814107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antithrombotic prophylaxis and treatment in thrombophilic disorders in gynaecology and obstetrics].
    Dulícek P; Penka M; Binder T; Unzeitig V
    Vnitr Lek; 2006 Mar; 52 Suppl 1():58-62. PubMed ID: 16637451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular Disease Patient Information Page: Cancer-associated thrombosis.
    Evans NS; Khorana AA
    Vasc Med; 2020 Jun; 25(3):286-288. PubMed ID: 32384252
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk factors for venous thromboembolism in children.
    Gerotziafas GT
    Int Angiol; 2004 Sep; 23(3):195-205. PubMed ID: 15765033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testosterone, thrombophilia, thrombosis.
    Freedman J; Glueck CJ; Prince M; Riaz R; Wang P
    Transl Res; 2015 May; 165(5):537-48. PubMed ID: 25639953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improve the results of phase II trials of thromboprophylaxis with the new oral anticoagulant drugs.
    Zufferey PJ; Samama CM; Rosencher N
    Thromb Haemost; 2010 Dec; 104(6):1083-4. PubMed ID: 20886198
    [No Abstract]   [Full Text] [Related]  

  • 15. Elevated risk of venous thromboembolic events in patients with inflammatory myopathies.
    Nowak M; Królak-Nowak K; Sobolewska-Włodarczyk A; Fichna J; Włodarczyk M
    Vasc Health Risk Manag; 2016; 12():233-8. PubMed ID: 27350751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inherited and acquired risk factors for venous thromboembolism.
    Baglin T
    Semin Respir Crit Care Med; 2012 Apr; 33(2):127-37. PubMed ID: 22648484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming challenges of venous thromboembolism in sickle cell disease treatment.
    Ogunsile FJ; Naik R; Lanzkron S
    Expert Rev Hematol; 2019 Mar; 12(3):173-182. PubMed ID: 30773073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer related thrombophilia: clinical importance and management strategies.
    Gupta PK; Charan VD; Kumar H
    J Assoc Physicians India; 2005 Oct; 53():877-82. PubMed ID: 16459532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Thrombophilic conditions in the pathogenesis of venous thromboembolism].
    Poul H
    Vnitr Lek; 2006 Mar; 52 Suppl 1():17-25. PubMed ID: 16637445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inherited thrombophilia and venous thromboembolism.
    Simioni P; Tormene D; Spiezia L; Tognin G; Rossetto V; Radu C; Prandoni P
    Semin Thromb Hemost; 2006 Oct; 32(7):700-8. PubMed ID: 17024597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.